# OnCo record zanubrutinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zanubrutinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zanubrutinib" ;
  schema:name "Zanubrutinib"@en ;
  schema:description "Zanubrutinib is the only BTK blocker to beat ibrutinib on both efficacy and safety in a head-to-head trial. It is now the most prescribed BTK inhibitor in CLL."@en ;
  schema:url <https://onco.cc/drugs/zanubrutinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Zanubrutinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q75192022> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Zanubrutinib> ;
  onco:status "approved" ;
  onco:modality "Small-molecule covalent BTK inhibitor (second generation)" ;
  schema:alternateName "Brukinsa" ;
  onco:approval "US 2019: Relapsed MCL (accelerated)", "US 2023: CLL/SLL, all lines (SEQUOIA, ALPINE)" ;
  onco:acceleratedApproval "US 2019-11-14: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.", "US 2021-09-14: Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen", "US 2024-03-07: Adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy", "US 2025-06-10: Formulation: Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.", "US 2025-06-10: Formulation: Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.", "US 2025-06-10: Formulation: Treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy." ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/cll-treatment-naive/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:companies <https://onco.cc/companies/beone/> ;
  onco:trials <https://onco.cc/trials/alpine/>, <https://onco.cc/trials/sequoia/>, <https://onco.cc/trials/celestial-tncll/>, <https://onco.cc/trials/nct04002297/>, <https://onco.cc/trials/nct06742996/>, <https://onco.cc/trials/nct05100862/>, <https://onco.cc/trials/nct06697184/>, <https://onco.cc/trials/nct07277231/>, <https://onco.cc/trials/nct06634589/>, <https://onco.cc/trials/nct04170283/>, <https://onco.cc/trials/nct06375733/>, <https://onco.cc/trials/nct04662255/>, <https://onco.cc/trials/nct06637501/>, <https://onco.cc/trials/nct05952037/> .